Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 10,420,410 | 9,950,396 | 9,337,021 | 9,980,063 | 10,313,290 |
| Cost of Goods | 3,117,538 | 2,678,176 | 2,498,157 | 2,998,465 | 2,876,125 |
| Gross Profit | 7,302,869 | 7,272,220 | 6,838,863 | 6,981,599 | 7,437,163 |
| Operating Expenses | 7,057,590 | 5,194,979 | 4,949,551 | 6,269,159 | 4,970,047 |
| Operating Income | 245,813 | 2,077,417 | 1,889,469 | 712,907 | 2,467,239 |
| Interest Expense | 202,894 | 219,605 | 210,505 | 276,532 | 230,394 |
| Other Income | 40,319 | 29,027 | 39,312 | 34,863 | 30,382 |
| Pre-tax Income | 83,238 | 1,886,839 | 1,718,276 | 471,237 | 2,267,227 |
| Income Tax | -1,301 | 241,061 | 347,459 | -23,241 | 325,336 |
| Net Income Continuous | 84,539 | 1,645,778 | 1,370,816 | 494,477 | 1,941,891 |
| Minority Interests | 159,974 | 165,335 | 44,384 | 61,278 | 88,613 |
| Net Income | $-75,435 | $1,480,443 | $1,326,432 | $433,199 | $1,853,278 |
| EPS Basic Total Ops | -0.04 | 0.73 | 0.65 | 0.21 | 0.91 |
| EPS Basic Continuous Ops | 0.04 | 0.81 | 0.67 | 0.24 | 0.96 |
| EPS Diluted Total Ops | -0.04 | 0.72 | 0.64 | 0.20 | 0.90 |
| EPS Diluted Continuous Ops | 0.04 | 0.80 | 0.67 | 0.23 | 0.94 |
| EPS Diluted Before Non-Recurring Items | N/A | 1.09 | 1.09 | 0.72 | 1.26 |
| EBITDA(a) | $1,528,423 | $2,880,605 | $2,585,657 | $1,451,092 | $3,215,265 |